Corbus Pharmaceuticals ( (CRBP) ) has shared an announcement.
Corbus Pharmaceuticals has unveiled promising pre-clinical data for CRB-913, a CB1 receptor inverse agonist targeting obesity, at Obesity Week 2024. CRB-913 showcased significant weight loss in mice, with brain levels 15 times lower than monlunabant, enhancing its peripheral efficacy. This innovative treatment maintained weight loss post-semaglutide withdrawal and even doubled fat loss compared to semaglutide alone, highlighting its potential for monotherapy and maintenance therapy. A Phase 1 study is anticipated in early 2025, marking a pivotal step in obesity treatment advancements.
Learn more about CRBP stock on TipRanks’ Stock Analysis page.